arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Moleculin Biotech, Inc.

MBRX
$0.41 ▲ +0.02 (+6.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Moleculin Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -41.0%
FCF / Share $-1.48
Trailing P/E
Price / Book 0.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-12.85M
↓ -99.6%
FCF / Share Free cash flow per share
$-1.48
↓ -203.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 44 quarters